Compare Stocks: IKT, ANRO, SPTX, and CRON

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANRO Alto Neuroscience	$31.98 -6.1%	$30.39	$3.59 ▼ $37.48	$1.27B	1.13	381,504 shs	478,186 shs
CRON Cronos Group	$3.16 +0.2%	$3.02	$2.28 ▼ $3.61	$1.16B	0.94	1.33 million shs	229,258 shs
IKT Inhibikase Therapeutics	$2.34 -3.1%	$2.30	$1.33 ▼ $2.61	$327.22M	0.95	1.15 million shs	112,064 shs
SPTX Seaport Therapeutics	$22.31 +2.6%	$22.39	$14.85 ▼ $28.38	$1.19B	N/A	203,369 shs	45,726 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANRO Alto Neuroscience	-4.92%	-7.49%	+20.17%	+59.15%	+800.53%
CRON Cronos Group	-0.94%	-2.78%	+5.00%	+14.34%	+23.53%
IKT Inhibikase Therapeutics	-0.82%	-3.60%	-2.03%	+44.31%	+44.31%
SPTX Seaport Therapeutics	-9.60%	-12.69%	-5.52%	+22.74%	+2,174,999,900.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANRO Alto Neuroscience	$31.98 -6.1%	$30.39	$3.59 ▼ $37.48	$1.27B	1.13	381,504 shs	478,186 shs
CRON Cronos Group	$3.16 +0.2%	$3.02	$2.28 ▼ $3.61	$1.16B	0.94	1.33 million shs	229,258 shs
IKT Inhibikase Therapeutics	$2.34 -3.1%	$2.30	$1.33 ▼ $2.61	$327.22M	0.95	1.15 million shs	112,064 shs
SPTX Seaport Therapeutics	$22.31 +2.6%	$22.39	$14.85 ▼ $28.38	$1.19B	N/A	203,369 shs	45,726 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANRO Alto Neuroscience	-4.92%	-7.49%	+20.17%	+59.15%	+800.53%
CRON Cronos Group	-0.94%	-2.78%	+5.00%	+14.34%	+23.53%
IKT Inhibikase Therapeutics	-0.82%	-3.60%	-2.03%	+44.31%	+44.31%
SPTX Seaport Therapeutics	-9.60%	-12.69%	-5.52%	+22.74%	+2,174,999,900.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANRO Alto Neuroscience	2.64	Moderate Buy	$37.25	16.48% Upside
CRON Cronos Group	2.60	Moderate Buy	$2.30	-27.10% Downside
IKT Inhibikase Therapeutics	3.00	Buy	$5.40	131.26% Upside
SPTX Seaport Therapeutics	2.36	Hold	$37.33	67.34% Upside

Current Analyst Ratings Breakdown

Latest IKT, ANRO, SPTX, and CRON Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/10/2026	SPTX Seaport Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$50.00
8/26/2026	CRON Cronos Group	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C+) ➝ Buy (B-)
8/26/2026	SPTX Seaport Therapeutics	JonesTrading Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$32.00
8/20/2026	ANRO Alto Neuroscience	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/20/2026	SPTX Seaport Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$50.00
8/17/2026	ANRO Alto Neuroscience	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$50.00 ➝ $55.00
8/13/2026	ANRO Alto Neuroscience	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$24.00 ➝ $26.00
8/13/2026	ANRO Alto Neuroscience	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$28.00 ➝ $37.00
8/12/2026	CRON Cronos Group	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D+) ➝ Hold (C+)
8/11/2026	SPTX Seaport Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Sell (D+)
8/4/2026	SPTX Seaport Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$50.00

(Data available from 9/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANRO Alto Neuroscience	N/A	N/A	N/A	N/A	$4.87 per share	N/A
CRON Cronos Group	$146.59M	7.93	$0.01 per share	254.05	$3.00 per share	1.05
IKT Inhibikase Therapeutics	$260K	1,253.18	N/A	N/A	$2.30 per share	1.02
SPTX Seaport Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANRO Alto Neuroscience	-$63.24M	-$2.42	N/A	N/A	N/A	N/A	-46.46%	-39.09%	11/11/2026 (Estimated)
CRON Cronos Group	-$9.45M	$0.20	15.78	N/A	N/A	39.08%	4.85%	4.62%	11/5/2026 (Estimated)
IKT Inhibikase Therapeutics	-$48.26M	-$0.43	N/A	N/A	N/A	N/A	-42.80%	-40.58%	N/A
SPTX Seaport Therapeutics	-$74.88M	-$12.12	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest IKT, ANRO, SPTX, and CRON Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	ANRO Alto Neuroscience	-$0.7345	-$0.65	+$0.0845	-$0.65	N/A	N/A
8/11/2026	Q2 2026	IKT Inhibikase Therapeutics	-$0.09	-$0.11	-$0.02	-$0.11	N/A	N/A
8/6/2026	Q2 2026	CRON Cronos Group	$0.01	$0.09	+$0.08	$0.09	$44.20 million	$53.01 million
8/3/2026	Q2 2026	SPTX Seaport Therapeutics	-$0.71	-$1.78	-$1.07	-$1.78	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANRO Alto Neuroscience	N/A	N/A	N/A	N/A	N/A
CRON Cronos Group	N/A	N/A	N/A	N/A	N/A
IKT Inhibikase Therapeutics	N/A	N/A	N/A	N/A	N/A
SPTX Seaport Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANRO Alto Neuroscience	0.07	14.85	14.85
CRON Cronos Group	N/A	16.18	15.25
IKT Inhibikase Therapeutics	N/A	15.82	15.82
SPTX Seaport Therapeutics	N/A	18.00	18.00

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANRO Alto Neuroscience	N/A
CRON Cronos Group	8.71%
IKT Inhibikase Therapeutics	3.81%
SPTX Seaport Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
ANRO Alto Neuroscience	11.25%
CRON Cronos Group	7.80%
IKT Inhibikase Therapeutics	7.10%
SPTX Seaport Therapeutics	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANRO Alto Neuroscience	N/A	39.24 million	34.83 million	N/A
CRON Cronos Group	450	368.54 million	339.80 million	Optionable
IKT Inhibikase Therapeutics	6	139.54 million	129.63 million	N/A
SPTX Seaport Therapeutics	N/A	53.53 million	N/A	N/A

IKT, ANRO, SPTX, and CRON Headlines

Recent News About These Companies

HC Wainwright Reaffirms Buy Rating for Seaport Therapeutics (NASDAQ:SPTX)

4 hours ago | marketbeat.com

Seaport Therapeutics Says GlyphAllo Shows no Next-Morning Driving Impairment in Phase 1 Trial

September 9 at 7:12 PM | finance.yahoo.com

Seaport Therapeutics Reports Positive Topline Results From Phase 1 Driving Simulation Trial Of GlyphAllo In Healthy Volunteers

September 9 at 2:12 PM | marketscreener.comM

Seaport Reports Positive GlyphAllo Driving Trial Results In Healthy Volunteers

September 9 at 2:12 PM | rttnews.com

PureTech Founded Entity Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers

September 9 at 2:00 PM | businesswire.com

Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers

September 9 at 8:44 AM | finance.yahoo.com

Citadel Advisors LLC Takes Position in Seaport Therapeutics, Inc. $SPTX

September 8 at 4:39 AM | marketbeat.com

Seaport Therapeutics, Inc. (NASDAQ:SPTX) Receives $37.33 Consensus PT from Analysts

September 8 at 3:44 AM | americanbankingnews.com

Braidwell LP Takes $10.86 Million Position in Seaport Therapeutics, Inc. $SPTX

September 3, 2026 | marketbeat.com

Seaport Therapeutics, Inc. (NASDAQ:SPTX) Given Consensus Rating of "Hold" by Analysts

September 3, 2026 | marketbeat.com

Alyeska Investment Group L.P. Makes New $1.63 Million Investment in Seaport Therapeutics, Inc. $SPTX

September 2, 2026 | marketbeat.com

Seaport Therapeutics to Present at Citi’s 2026 Biopharma Back to School Conference and Participate in 21st Annual Wells Fargo Healthcare Conference

August 31, 2026 | finance.yahoo.com

Seaport Therapeutics (NASDAQ:SPTX) Stock Price Down 5.2% - Here's Why

August 27, 2026 | marketbeat.com

Seaport Therapeutics (NASDAQ:SPTX) Stock Price Up 6.4% - Time to Buy?

August 26, 2026 | marketbeat.com

Seaport Therapeutics (NASDAQ:SPTX) Now Covered by Analysts at JonesTrading

August 26, 2026 | marketbeat.com

Seaport Therapeutics (NASDAQ:SPTX) Sets New 52-Week High - Here's Why

August 24, 2026 | marketbeat.com

Seaport Therapeutics' (SPTX) Buy Rating Reaffirmed at HC Wainwright

August 20, 2026 | marketbeat.com

Trv Gp Vi LLC Purchases New Holdings in Seaport Therapeutics, Inc. $SPTX

August 19, 2026 | marketbeat.com

Seaport Therapeutics (NASDAQ:SPTX) Reaches New 52-Week High - Here's What Happened

August 18, 2026 | marketbeat.com

Seaport Therapeutics: A Development-Arbitrage Platform With Two Layers Of Validation

August 11, 2026 | seekingalpha.com

Seaport Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress

August 3, 2026 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IKT, ANRO, SPTX, and CRON Company Descriptions

Alto Neuroscience NYSE:ANRO

$31.98 -2.09 (-6.13%)

As of 12:20 PM Eastern

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder. The company develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties which is in phase 2b clinical trial to treat patients with MDD; ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor which is in phase 1 clinical trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist which is in phase 1 clinical trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor which is in phase 1 clinical trial for the treatment of MDD. In addition, it develops novel pharmacodynamically synergistic combination and biomarker platform that collects patient-specific data to identify biomarker-characterized patient. The company was incorporated in 2019 and is headquartered in Los Altos, California.

Cronos Group NASDAQ:CRON

$3.16 +0.01 (+0.16%)

As of 12:19 PM Eastern

Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.

Inhibikase Therapeutics NASDAQ:IKT

$2.34 -0.08 (-3.11%)

As of 12:19 PM Eastern

Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.

Seaport Therapeutics NASDAQ:SPTX

$22.31 +0.56 (+2.57%)

As of 11:43 AM Eastern

Seaport Therapeutics Inc. is a clinical-stage therapeutics company focused on inventing and developing new medicines for patients with depression, anxiety and other debilitating neuropsychiatric disorders. Seaport Therapeutics Inc. is based in BOSTON.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IKT, ANRO, SPTX, and CRON Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IKT, ANRO, SPTX, and CRON Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IKT, ANRO, SPTX, and CRON Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

IKT, ANRO, SPTX, and CRON Company Descriptions

Alto Neuroscience NYSE:ANRO

Cronos Group NASDAQ:CRON

Inhibikase Therapeutics NASDAQ:IKT

Seaport Therapeutics NASDAQ:SPTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IKT, ANRO, SPTX, and CRON Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IKT, ANRO, SPTX, and CRON Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IKT, ANRO, SPTX, and CRON Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

IKT, ANRO, SPTX, and CRON Company Descriptions

Alto Neuroscience NYSE:ANRO

Cronos Group NASDAQ:CRON

Inhibikase Therapeutics NASDAQ:IKT

Seaport Therapeutics NASDAQ:SPTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools